HCA (HCA) Q1 2026 Earnings Call Transcript

HCA Healthcare reported Q1 revenue up 4.3% and adjusted diluted EPS up 11%, with adjusted EBITDA rising nearly 2% despite a 50 bps margin decline from higher operating expenses. The quarter was pressured by a $180 million hit from weak respiratory volumes and winter weather, but this was largely offset by a $200 million net benefit from Medicaid supplemental programs, led by Georgia and Texas. Management reaffirmed 2026 guidance, including 2% to 3% volume growth, a $400 million resiliency target, and a $600 million to $900 million exchange-related EBITDA impact.

Analysis

HCA is telling us the core earnings engine is still intact, but the quarter exposed how much of the near-term debate is now about timing rather than trajectory. The biggest second-order takeaway is that supplemental payments and exchange attrition are becoming a more important swing factor than underlying utilization, which means consensus will likely overreact to quarterly print noise while underestimating how much of the EBITDA bridge is already “pre-modeled” for the rest of the year.

The real hidden positive is capital intensity as a growth lever: management is still adding beds, ER capacity, and outpatient footprint while buying back stock aggressively. That combination is unusual for a mature hospital operator and should keep per-share growth ahead of reported operating growth, especially if cost-resiliency and AI tools continue to offset wage pressure. The market may also be missing that the service-line mix is quietly improving toward higher-acuity, higher-margin business, which gives HCA more pricing power than a simple admissions story suggests.

The main risk is that the exchange deterioration and Medicaid conversion slowdown are not just one-quarter timing issues but an early-stage mix shift that takes longer to stabilize. If uninsured growth persists into the back half of the year, the earnings sensitivity is less about gross volumes and more about collections, denials, and bad debt, which can compress margins even when revenue holds up. North Carolina is the other underappreciated watchpoint: elevated cost-to-serve in a high-demand market can turn a volume win into a margin headwind if labor normalization lags.

Consensus likely still underweights how much HCA can self-help through contracting, revenue-cycle optimization, and capital deployment. The stock should remain supported unless the exchange/Medicaid issue broadens materially or supplemental approvals roll over faster than expected; otherwise, the asymmetry still favors owning the business through the next 2-3 quarters rather than trading the quarter.

Key Decisions for Investors

• Long HCA on pullbacks over the next 2-6 weeks: the setup favors earnings compounding plus buybacks, with downside largely tied to a slower-than-expected exchange reset rather than core demand.
• If you need a hedge, pair long HCA vs short a higher-beta managed care or ACA-exposed name for the next 1-2 quarters; HCA has better control over reimbursement realization and operating leverage.
• Consider a call spread in HCA into the next earnings cycle (3-6 month tenor): the stock can rerate if management confirms the exchange headwind is stabilizing and supplemental approvals remain additive.
• Avoid chasing after strength until there is evidence that Medicaid conversion and uninsured mix have peaked; that is the key variable that could pressure cash collections over the next 1-2 quarters.
• Use any selloff tied to North Carolina headlines as a buying opportunity unless there is evidence of system-wide margin leakage; that issue appears local, not thesis-breaking.